Post engagements
Back to post- Great fun to write this perspective with @lukasbunse.bsky.social @platten-lab.bsky.social @dkfz-iic.bsky.social @dkfz.bsky.social on a highly interesting study by the Bardeesy Lab. This study provides additional mechanistic rationale to combine IDH inhibitors with T cell activating therapies.
- A recent study unpicks a key immune-mediated mechanism of mutant IDH–blocking drugs such as vorasidenib in the treatment of IDH-mutant glioma. Learn more in a new Clinical Implications of Basic Research article: nej.md/4f3dIMf #MedSky
